UnknownPhase 2NCT03943602
Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen)
Studying Squamous cell carcinoma of the penis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Principal Investigator
- Daniele Raggi, MDFondazione IRCCS ISTITUTO NAZIONALE TUMORI
- Intervention
- Cabozantinib(drug)
- Enrollment
- 37 target
- Eligibility
- 18-75 years · MALE
- Timeline
- 2019 – 2022
Study locations (1)
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03943602 on ClinicalTrials.govOther trials for Squamous cell carcinoma of the penis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06666634Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node BiopsyThe Netherlands Cancer Institute
- RECRUITINGPHASE2NCT05526989Study of the Combination Dostarlimab With Niraparib In Patients With Penile CarcinomaH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGPHASE3NCT02305654International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)Institute of Cancer Research, United Kingdom